Blueprint Medicines (BPMC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...

Analyst Ami Fadia of Needham maintained a Buy rating on Blueprint Medicines (BPMC – Research Report), retaining the price target of ...

Fintel reports that on November 14, 2024, JP Morgan initiated coverage of Blueprint Medicines (NasdaqGS:BPMC) with a ...

JP Morgan initiated coverage on Blueprint Medicines Corporation (NASDAQ:BPMC), a biotech company focused on modulating immune ...

On Thursday, Needham maintained a Buy rating on shares of Blueprint Medicines (NASDAQ:BPMC) and increased the price target to $135 from $133. The adjustment comes after the company reported robust ...

Ami Fadia; Analyst; Needham & Company Inc. Thank you, Nadia. Good morning, everyone, and welcome to Blueprint Medicines third-quarter 2024 financial and operating results conference call.

Ami Fadia; Analyst; Needham & Company Inc. Thank you, Nadia. Good morning, everyone, and welcome to Blueprint Medicines third-quarter 2024 financial and operating results conference call. This morning ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

At this time, I would like to welcome everyone to the Blueprint Medicines Third Quarter 2024 Financial Results Conference Call. [Operator Instructions] Thank you. Jenna Cohen, you may begin your ...

On Wednesday, Blueprint Medicines (NASDAQ:BPMC) received a reiteration of a Buy rating and a $155.00 price target from Stifel. The firm's analyst highlighted the company's recent performance, ...